Jul 22, 2023, 17:56
High response rates in poor-risk population – Hagop Kantarjian
Our study of aza + ven + pevonedistat NEDD8-activating enzyme inhibitor in secondary AML & MDS/CMML after HMA failure. High response rates in poor-risk population. Data from randomized ph3 study in AML are awaited.
For article: Click here
Source: Hagop Kantarjian/Twitter